Helen Burton-Murray, Aluma Chovel Sella, Julia E. Gydus, Micaela Atkins, Lilian P. Palmer, Megan C. Kuhnle, Kendra R. Becker, Lauren E. Breithaupt, Kathryn S. Brigham, Anna Aulinas, Kyle Staller, Kamryn T. Eddy, Madhusmita Misra, Nadia Micali, Jennifer J. Thomas, Elizabeth A. Lawson
{"title":"Medical Comorbidities, Nutritional Markers, and Cardiovascular Risk Markers in Youth With ARFID","authors":"Helen Burton-Murray, Aluma Chovel Sella, Julia E. Gydus, Micaela Atkins, Lilian P. Palmer, Megan C. Kuhnle, Kendra R. Becker, Lauren E. Breithaupt, Kathryn S. Brigham, Anna Aulinas, Kyle Staller, Kamryn T. Eddy, Madhusmita Misra, Nadia Micali, Jennifer J. Thomas, Elizabeth A. Lawson","doi":"10.1002/eat.24243","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Avoidant/restrictive food intake disorder (ARFID) is common among populations with nutrition-related medical conditions. Less is known about the medical comorbidity/complication frequencies in youth with ARFID. We evaluated the medical comorbidities and metabolic/nutritional markers among female and male youth with full/subthreshold ARFID across the weight spectrum compared with healthy controls (HC).</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>In youth with full/subthreshold ARFID (<i>n</i> = 100; 49% female) and HC (<i>n</i> = 58; 78% female), we assessed self-reported medical comorbidities via clinician interview and explored abnormalities in metabolic (lipid panel and high-sensitive C-reactive protein [hs-CRP]) and nutritional (25[OH] vitamin D, vitamin B12, and folate) markers.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Youth with ARFID, compared with HC, were over 10 times as likely to have self-reported gastrointestinal conditions (37% vs. 3%; OR = 21.2; 95% CI = 6.2–112.1) and over two times as likely to have self-reported immune-mediated conditions (42% vs. 24%; OR = 2.3; 95% CI = 1.1–4.9). ARFID, compared with HC, had a four to five times higher frequency of elevated triglycerides (28% vs. 12%; OR = 4.0; 95% CI = 1.7–10.5) and hs-CRP (17% vs. 4%; OR = 5.0; 95% CI = 1.4–27.0) levels.</p>\n </section>\n \n <section>\n \n <h3> Discussion</h3>\n \n <p>Self-reported gastrointestinal and certain immune comorbidities were common in ARFID, suggestive of possible bidirectional risk/maintenance factors. Elevated cardiovascular risk markers in ARFID may be a consequence of limited dietary variety marked by high carbohydrate and sugar intake.</p>\n </section>\n </div>","PeriodicalId":51067,"journal":{"name":"International Journal of Eating Disorders","volume":"57 11","pages":"2167-2175"},"PeriodicalIF":4.7000,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Eating Disorders","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/eat.24243","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
Avoidant/restrictive food intake disorder (ARFID) is common among populations with nutrition-related medical conditions. Less is known about the medical comorbidity/complication frequencies in youth with ARFID. We evaluated the medical comorbidities and metabolic/nutritional markers among female and male youth with full/subthreshold ARFID across the weight spectrum compared with healthy controls (HC).
Method
In youth with full/subthreshold ARFID (n = 100; 49% female) and HC (n = 58; 78% female), we assessed self-reported medical comorbidities via clinician interview and explored abnormalities in metabolic (lipid panel and high-sensitive C-reactive protein [hs-CRP]) and nutritional (25[OH] vitamin D, vitamin B12, and folate) markers.
Results
Youth with ARFID, compared with HC, were over 10 times as likely to have self-reported gastrointestinal conditions (37% vs. 3%; OR = 21.2; 95% CI = 6.2–112.1) and over two times as likely to have self-reported immune-mediated conditions (42% vs. 24%; OR = 2.3; 95% CI = 1.1–4.9). ARFID, compared with HC, had a four to five times higher frequency of elevated triglycerides (28% vs. 12%; OR = 4.0; 95% CI = 1.7–10.5) and hs-CRP (17% vs. 4%; OR = 5.0; 95% CI = 1.4–27.0) levels.
Discussion
Self-reported gastrointestinal and certain immune comorbidities were common in ARFID, suggestive of possible bidirectional risk/maintenance factors. Elevated cardiovascular risk markers in ARFID may be a consequence of limited dietary variety marked by high carbohydrate and sugar intake.
期刊介绍:
Articles featured in the journal describe state-of-the-art scientific research on theory, methodology, etiology, clinical practice, and policy related to eating disorders, as well as contributions that facilitate scholarly critique and discussion of science and practice in the field. Theoretical and empirical work on obesity or healthy eating falls within the journal’s scope inasmuch as it facilitates the advancement of efforts to describe and understand, prevent, or treat eating disorders. IJED welcomes submissions from all regions of the world and representing all levels of inquiry (including basic science, clinical trials, implementation research, and dissemination studies), and across a full range of scientific methods, disciplines, and approaches.